Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

135 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Adenovirus-5-vectored P. falciparum vaccine expressing CSP and AMA1. Part B: safety, immunogenicity and protective efficacy of the CSP component.
Tamminga C, Sedegah M, Regis D, Chuang I, Epstein JE, Spring M, Mendoza-Silveiras J, McGrath S, Maiolatesi S, Reyes S, Steinbeiss V, Fedders C, Smith K, House B, Ganeshan H, Lejano J, Abot E, Banania GJ, Sayo R, Farooq F, Belmonte M, Murphy J, Komisar J, Williams J, Shi M, Brambilla D, Manohar N, Richie NO, Wood C, Limbach K, Patterson NB, Bruder JT, Doolan DL, King CR, Diggs C, Soisson L, Carucci D, Levine G, Dutta S, Hollingdale MR, Ockenhouse CF, Richie TL. Tamminga C, et al. Among authors: sedegah m. PLoS One. 2011;6(10):e25868. doi: 10.1371/journal.pone.0025868. Epub 2011 Oct 7. PLoS One. 2011. PMID: 22003411 Free PMC article. Clinical Trial.
It is one component of a two-component vaccine NMRC-M3V-Ad-PfCA consisting of one adenovector encoding CSP and one encoding apical membrane antigen-1 (AMA1) that was evaluated for safety and immunogenicity in an earlier study (see companion paper, Sedegah et al). Fourteen …
It is one component of a two-component vaccine NMRC-M3V-Ad-PfCA consisting of one adenovector encoding CSP and one encoding apical membrane …
Safety, immunogenicity, and efficacy of a malaria sporozoite vaccine administered with monophosphoryl lipid A, cell wall skeleton of mycobacteria, and squalane as adjuvant.
Hoffman SL, Edelman R, Bryan JP, Schneider I, Davis J, Sedegah M, Gordon D, Church P, Gross M, Silverman C, et al. Hoffman SL, et al. Among authors: sedegah m. Am J Trop Med Hyg. 1994 Nov;51(5):603-12. doi: 10.4269/ajtmh.1994.51.603. Am J Trop Med Hyg. 1994. PMID: 7985753 Clinical Trial.
Nucleic acid malaria vaccines. Current status and potential.
Hoffman SL, Doolan DL, Sedegah M, Gramzinski R, Wang H, Gowda K, Hobart P, Margalith M, Norman J, Hedstrom RC. Hoffman SL, et al. Among authors: sedegah m. Ann N Y Acad Sci. 1995 Nov 27;772:88-94. doi: 10.1111/j.1749-6632.1995.tb44734.x. Ann N Y Acad Sci. 1995. PMID: 8546416 Review. No abstract available.
Malaria DNA vaccines in Aotus monkeys.
Gramzinski RA, Maris DC, Doolan D, Charoenvit Y, Obaldia N, Rossan R, Sedegah M, Wang R, Hobart P, Margalith M, Hoffman S. Gramzinski RA, et al. Among authors: sedegah m. Vaccine. 1997 Jun;15(8):913-5. doi: 10.1016/s0264-410x(96)00270-8. Vaccine. 1997. PMID: 9234546
DNA vaccines for malaria: the past, the present, & the future.
Doolan DL, Hedstrom RC, Wang R, Sedegah M, Scheller LF, Hobart P, Norman JA, Hoffman SL. Doolan DL, et al. Among authors: sedegah m. Indian J Med Res. 1997 Aug;106:109-19. Indian J Med Res. 1997. PMID: 9291681 Review.
135 results